Medtronic reports 88.1% ulcer healing rate at 24 months in VenaSeal venous leg ulcer study

By Public Technologies
  • Medtronic reported new 24-month results from its VenaSeal Spectrum Venous Leg Ulcer study, presented at the 2026 VEINS conference.
  • Data showed the device supported durable ulcer healing, symptom relief, quality-of-life gains, sustained vein closure, low repeat-treatment needs.
  • Management framed the evidence as strengthening physician confidence in VenaSeal for advanced chronic venous disease, including active ulcers.
  • U.S. commercial and Medicare coverage expanded to 96% of insured lives, lowering reimbursement friction for broader adoption.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medtronic plc published the original content used to generate this news brief on October 03, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.